MoonLake Immunotherapeutics (MLTX)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
MoonLake Immunotherapeutics
NASDAQ:MLTXHealthcare · Biotechnology
AHAfter hours-1.51%$12.43
Prev close$11.53+9.45%Close$12.62-1.51%Now$12.43
Close$12.62+9.45%
Mkt Cap$1.07B
Float54.6M
O/S85.11M
VOL1.58M sh
$ Vol$19.87M
RVOL0.94×
Inst Own85.6%
Dilution
Historical Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 9, 2026 | 11.82 | 12.91 | 11.59 | 12.62 | 1,592,627 |
| Nov 6, 2026 | 11.14 | 11.55 | 11.01 | 11.53 | 1,033,955 |
| Nov 5, 2026 | 11.11 | 11.61 | 10.66 | 10.80 | 1,337,583 |
| Nov 4, 2026 | 11.86 | 11.93 | 10.95 | 11.56 | 1,226,081 |
| Nov 3, 2026 | 11.52 | 11.72 | 11.29 | 11.70 | 855,037 |
| Nov 2, 2026 | 11.80 | 11.99 | 11.17 | 11.47 | 972,019 |
| Oct 30, 2026 | 12.44 | 12.63 | 11.71 | 11.78 | 1,128,536 |
| Oct 29, 2026 | 12.36 | 12.95 | 12.31 | 12.57 | 4,097,291 |
| Oct 28, 2026 | 11.87 | 12.38 | 11.71 | 12.31 | 1,205,061 |
| Oct 27, 2026 | 11.77 | 12.10 | 11.54 | 11.93 | 934,417 |
| Oct 26, 2026 | 11.77 | 12.46 | 11.66 | 11.81 | 1,514,732 |
| Oct 23, 2026 | 12.07 | 12.28 | 11.48 | 11.85 | 1,935,821 |
| Oct 22, 2026 | 10.70 | 13.33 | 10.65 | 12.34 | 6,120,091 |
| Oct 21, 2026 | 10.34 | 10.73 | 10.34 | 10.65 | 1,163,638 |
| Oct 20, 2026 | 9.77 | 10.48 | 9.73 | 10.32 | 1,237,764 |
| Oct 19, 2026 | 9.57 | 9.86 | 9.50 | 9.75 | 911,741 |
| Oct 16, 2026 | 10.34 | 10.34 | 9.46 | 9.55 | 1,380,990 |
| Oct 15, 2026 | 10.16 | 10.51 | 10.14 | 10.26 | 1,067,279 |
| Oct 14, 2026 | 10.30 | 10.65 | 10.01 | 10.14 | 1,772,987 |
| Oct 13, 2026 | 10.70 | 10.84 | 10.36 | 10.41 | 2,412,553 |
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$50.00+296.2%
Low $50High $50
Ratings Distribution
BUY15
HOLD2
SELL2
TOTAL19
Insider Trades
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Reich Kristian | Chief Scientific Officer | Sale | 1.1K | $22.0K | Jul 27, 2026 |
| Reich Kristian | Chief Scientific Officer | Sale | 2.4K | $49.0K | Jul 22, 2026 |
| Reich Kristian | Chief Scientific Officer | Sale | 50.0K | $1.00M | Jul 21, 2026 |
| Reich Kristian | Chief Scientific Officer | Sale | 43.7K | $877.9K | Jul 20, 2026 |
| Reich Kristian | Chief Scientific Officer | Sale | 16.1K | $322.3K | Jul 15, 2026 |
 Santos da Silva Jorge | Chief Executive Officer | Sale | 68.3K | $1.37M | Jul 10, 2026 |
Shareholders
85.6%
Institutional
(173)
4.8%
Insiderⓘ
(5)
3.3%
5%+ Owners
(1)
of which 3.3% rests on schedules older than 24 months (1 holder)
6.3%
Unattributed (incl. retail)ⓘ
Institutional85.6%
Insider4.8%
5%+ Beneficial3.3%
Unattributed (incl. retail)6.3%
Top Shareholders
| Name | Shares | % | Source |
|---|---|---|---|
BVF INC/IL | 16.0M | 18.8% | 13F |
BVF PARTNERS L P/IL · also on 13F· joint filing· may incl. warrants· filed Jun 2026 | 16.0M | 18.8% | 13D |
Deep Track Capital, LP | 7.0M | 8.2% | 13F |
FMR LLC · also on 13F· may incl. warrants· filed Nov 2024 | 4.9M | 5.8% | 13G |
Deep Track Capital, LP · also on 13F· may incl. warrants· filed Nov 2025 | 4.6M | 5.4% | 13G |
Cormorant Asset Management, LP · also on 13F· joint filing· may incl. warrants· filed May 2026 | 4.5M | 5.3% | 13G |
T. Rowe Price Investment Management, Inc. | 4.3M | 5.0% | 13F |
T. Rowe Price Investment Management, Inc. · also on 13F· may incl. warrants· filed Aug 2026 | 4.3M | 5.0% | 13G |
D. E. Shaw & Co., Inc. | 3.4M | 4.0% | 13F |
Cormorant Asset Management, LP | 3.2M | 3.8% | 13F |
Sources: 13F, Form 4, 13D/13GO/S: 85.1M · as of 1 Nov 2026 · SEC cover page
Insiders & Institutional Holders
Insiders
- Reich KristianChief Scientific Officer
- Santos da Silva JorgeChief Executive Officer
- Bodenstedt MatthiasChief Financial Officer
- Moukheibir CatherineDirector
- Phillips Andrew JohnDirector
- Loy SpikeDirector
- Xavier RamnikDirector
- BVF PARTNERS L P/ILDirector
- Chen Bihua
- Sturge SimonDirector
About
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies.
The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Key Metrics
Market Cap$1.07B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership85.62%
based on 85.11M shares outstanding
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
Country
CH
CHIPO DateOct 20, 2020
Shares Outstanding85.11M
Authorized Shares
Float54.60M
52-Week Range
$9.46$23.29
$12.62(23rd percentile)
Volume
Average Daily Volume1.67M
1.59M today vs 1.67M avg(-5%)
30d Avg
1.67M
60d Avg
1.87M
90d Avg
1.65M
Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...